Click to zoom
Product Description
Combinib 250 mg Lapatinib IP is a targeted anti-cancer medication manufactured by Cipla. Primarily used to treat advanced or metastatic HER2-positive breast cancer, it is a tyrosine kinase inhibitor that blocks abnormal proteins driving cancer cell growth, often prescribed alongside capecitabine, trastuzumab, or hormonal therapies.
liketo.usa,uk,china,southkorea,russia,japan,singapore
Composition
Strength 250 mg
Packaging Size 30 Tablets
Pack Size 30 Tablets
Usage Breast Cancer
Manufactured By Cipla
Prescription/Non Prescription Prescription
Country of Origin Made in India
Composition Lapatinib Tablets IP
Brand Combinib
Form Tablet
Minimum order quantity: 50 Bottle
Shipping Information
We offer reliable delivery across India and international markets. Domestic orders are typically delivered within 5-7 business days. International shipping times vary by destination. All orders are carefully packaged to maintain product integrity.
500 mg CIPRODAC 500 CIPROFLOXACIN IP TABLETS
On Request
500 mg Ciplox-500 Ciprofloxacin Hydrochloride IP Tablets
On Request
12 mg Iverheal 12 Ivermectin Dispersible Tablets
On Request
500 mg Novamox-500 Amoxycillin Trihydrate IP Capsules
On Request
500 mg Methoflam-500 Methocarbamol IP Tablets
On Request
25 mg Baclosign-25 Baclofen Tablets
On Request
25 mg LENANAMO Lenalidomide Capsules
On Request
500 mg Captomer MERCAPTOPURINE I.P. TABLETS
On Request